Niklas Mattsson-Carlgren, MD, PhD
Niklas Mattsson-Carlgren, MD, PhD
Bestätigte E-Mail-Adresse bei
Zitiert von
Zitiert von
CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment
N Mattsson, H Zetterberg, O Hansson, N Andreasen, L Parnetti, ...
Jama 302 (4), 385-393, 2009
Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis
WJ Jansen, R Ossenkoppele, DL Knol, BM Tijms, P Scheltens, ...
Jama 313 (19), 1924-1938, 2015
Amyloid biomarkers in Alzheimer's disease
K Blennow, N Mattsson, M Schöll, O Hansson, H Zetterberg
Trends in pharmacological sciences 36 (5), 297-309, 2015
Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease
N Mattsson, U Andreasson, H Zetterberg, K Blennow
JAMA neurology 74 (5), 557-566, 2017
The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers
N Mattsson, U Andreasson, S Persson, H Arai, SD Batish, S Bernardini, ...
Alzheimer's & Dementia 7 (4), 386-395. e6, 2011
CSF biomarker variability in the Alzheimer's Association quality control program
N Mattsson, U Andreasson, S Persson, MC Carrillo, S Collins, S Chalbot, ...
Alzheimer's & Dementia 9 (3), 251-261, 2013
Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers
GB Frisoni, M Boccardi, F Barkhof, K Blennow, S Cappa, K Chiotis, ...
The Lancet Neurology 16 (8), 661-676, 2017
Earliest accumulation of β-amyloid occurs within the default-mode network and concurrently affects brain connectivity
S Palmqvist, M Schöll, O Strandberg, N Mattsson, E Stomrud, H Zetterberg, ...
Nature communications 8 (1), 1-13, 2017
Association of cerebrospinal fluid neurofilament light concentration with Alzheimer disease progression
H Zetterberg, T Skillbäck, N Mattsson, JQ Trojanowski, E Portelius, ...
JAMA neurology 73 (1), 60-67, 2016
CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios: better diagnostic markers of Alzheimer disease
S Janelidze, H Zetterberg, N Mattsson, S Palmqvist, H Vanderstichele, ...
Annals of clinical and translational neurology 3 (3), 154-165, 2016
The cerebrospinal fluid “Alzheimer profile”: easily said, but what does it mean?
FH Duits, CE Teunissen, FH Bouwman, PJ Visser, N Mattsson, ...
Alzheimer's & Dementia 10 (6), 713-723. e2, 2014
Plasma tau in Alzheimer disease
N Mattsson, H Zetterberg, S Janelidze, PS Insel, U Andreasson, ...
Neurology 87 (17), 1827-1835, 2016
Smoking and increased Alzheimer's disease risk: a review of potential mechanisms
TC Durazzo, N Mattsson, MW Weiner, ...
Alzheimer's & Dementia 10, S122-S145, 2014
Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease
S Palmqvist, H Zetterberg, N Mattsson, P Johansson, L Minthon, ...
Neurology 85 (14), 1240-1249, 2015
CSF neurofilament light differs in neurodegenerative diseases and predicts severity and survival
T Skillbäck, B Farahmand, JW Bartlett, C Rosén, N Mattsson, K Nägga, ...
Neurology 83 (21), 1945-1953, 2014
Blood-based NfL: a biomarker for differential diagnosis of parkinsonian disorder
O Hansson, S Janelidze, S Hall, N Magdalinou, AJ Lees, U Andreasson, ...
Neurology 88 (10), 930-937, 2017
Cerebrospinal fluid analysis detects cerebral amyloid-β accumulation earlier than positron emission tomography
S Palmqvist, N Mattsson, O Hansson, ...
Brain 139 (4), 1226-1236, 2016
Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease
N Mattsson, PS Insel, M Donohue, S Landau, WJ Jagust, LM Shaw, ...
Brain 138 (3), 772-783, 2015
Age and diagnostic performance of Alzheimer disease CSF biomarkers
N Mattsson, E Rosen, O Hansson, N Andreasen, L Parnetti, M Jonsson, ...
Neurology 78 (7), 468-476, 2012
Discontinuation of proton pump inhibitors in patients on long‐term therapy: a double‐blind, placebo‐controlled trial
E Björnsson, H Abrahamsson, M Simren, N Mattsson, C Jensen, ...
Alimentary pharmacology & therapeutics 24 (6), 945-954, 2006
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20